Brief: Bristol Myers Squibb Announces Opdivo® (Nivolumab) In Combination With Avd Receives Expanded EU Label With Approval In Frontline Advanced Classical Hodgkin Lymphoma
01/06/2026 12:27
BRIEF-Bristol Myers Squibb Announces Opdivo® (Nivolumab) In Combination With Avd Receives Expanded EU Label With Approval In Frontline Advanced Classical Hodgkin Lymphoma June 1 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS SQUIBB ANNOUNCES OPDIVO® (NIVOLUMAB) IN COMBINATION WITH AVD RECEIVES EXPANDED EU LABEL WITH APPROVAL IN FRONTLINE ADVANCED CLASSICAL HODGKIN LYMPHOMA
BRISTOL-MYERS SQUIBB: IMMUNOTHERAPY COMBINATION APPROVED FOR ADULT ADOLESCENT PATIENTS, AGES 12 OLDER, WITH PREVIOUSLY UNTREATED STAGE III/IV CHL
Source text: ID:nBw7MlmdBa
Further company coverage: BMY.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb Co
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Bristol Myers Squibb Announces Dividend
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC